logo-loader
Faron Pharmaceuticals Limited

Faron Pharma. Oy - Holdings in Company

RNS Number : 2122S
Faron Pharmaceuticals Oy
22 June 2018
 

TR-1: Standard form for notification of major holdings

 


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii

Faron Pharmaceuticals Oy
7437009H31TO1DC0EB42

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights


An acquisition or disposal of financial instruments


An event changing the breakdown of voting rights


Other (please specify)iiiDisclosure as per company's Articles of Association

X

3. Details of person subject to the notification obligationiv

Name

 

Legal & General Group Plc (Group)

 

Legal & General Investment Management Limited (LGIM)

 

Legal & General (Unit Trust Managers) Limited

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

4. Full name of shareholder(s) (if different from 3.)v

Name


Legal & General Assurance Society (LGAS)

 

City and country of registered office (if applicable)

1 Coleman St, London EC2R 5AA

5. Date on which the threshold was crossed or reachedvi:

19 June 2018

6. Date on which issuer notified (DD/MM/YYYY):

 

21 June 2018

 

 

7. Total positions of person(s) subject to the notification obligation


% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached (LGIM)

0.37%

-

0.37%

 

31,027,894

 

Position of previous notification (if

applicable) (LGIM)

1.53%

-

1.53%


Resulting situation on the date on which threshold was crossed or reached (UTM)

0.30%

-

0.30%

 

31,027,894

 

Position of previous notification (if

applicable) (UTM)

1.26%

-

1.26%


 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORD NPV

-

116,000

-

0.37%

SUBTOTAL 8. A

116,000

0.37%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights


















SUBTOTAL 8. B 1



 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration
date
x

Exercise/
Conversion Period
xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights






















SUBTOTAL 8.B.2




 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

 

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii


 

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
xiv (please add additional rows as necessary)

x

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 

Legal & General Group (Direct/Indirect)

0.37%


0.37%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

0.37%


0.37%

 

Legal & General Assurance Society (Direct)

0.06%


0.06%

 





 

Legal & General Group (Direct/Indirect)

0.37%


0.37%

 

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

0.37%


0.37%

Legal & General Assurance (Pensions Management) Limited

(Direct)

-


-





Legal & General Group (Direct/Indirect)

0.37%


0.37%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

0.37%


0.37%

Legal & General Investment Management Limited (Indirect)

0.37%


0.37%





Legal & General Group (Direct/Indirect)

0.37%


0.37%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

0.37%


0.37%

Legal & General (Unit Trust Managers) Limited (Indirect)

0.31%


0.31%





Legal & General Group (Direct/Indirect)

0.37%


0.37%

Legal & General Investment Management (Holdings) Limited

(Direct/Indirect)

0.37%


0.37%

Go ETF Solutions

-


-


 

In case of proxy voting, please identify:

 

Name of the proxy holder

N/A

 

The number and % of voting rights held

N/A

 

The date until which the voting rights will be held

N/A

 

 

 

 

11. Additional informationxvi

 

 

Notification using the total voting rights figure of 31,027,894

 

 

Place of completion

Brunel House, 2 Fitzalan Road, Cardiff, CF24 0EB

Date of completion

21/06/2018

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLLFLLLVQFXBBZ
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

Faron Pharmaceuticals reports promising phase 1 results from BEXMAB study

Faron Pharmaceuticals Limited (AIM:FARN) chief executive Dr Markku Jalkanen joins Proactive's Stephen Gunnion with additional positive data from the Phase 1 study of the ongoing bexmarilimab (BEXMAB) trial that has moved into Phase 2 for higher-risk (HR) myelodysplastic syndrome (MDS) patients...

1 week, 3 days ago

4 min read